Septerna (NASDAQ:SEPN) Sets New 1-Year Low – Here’s What Happened

Septerna, Inc. (NASDAQ:SEPN) shares hit a new 52-week low on Tuesday . The stock traded as low as $15.10 and last traded at $15.45, with a volume of 215 shares changing hands. The stock had previously closed at $15.61.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on SEPN. Wells Fargo & Company assumed coverage on Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $43.00 price target for the company. JPMorgan Chase & Co. assumed coverage on shares of Septerna in a research note on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 price target for the company. TD Cowen assumed coverage on Septerna in a report on Tuesday, November 19th. They set a “buy” rating on the stock. Finally, Cantor Fitzgerald began coverage on Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $50.00 price target on the stock.

Septerna Price Performance

The firm’s fifty day simple moving average is $21.55.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. New York State Common Retirement Fund bought a new position in shares of Septerna during the 4th quarter valued at $32,000. SG Americas Securities LLC bought a new position in shares of Septerna in the 4th quarter worth approximately $185,000. Finally, Rhumbline Advisers purchased a new position in shares of Septerna in the fourth quarter worth approximately $458,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.